Loteprednol Etabonate (Alrex)

An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.

Also Known As:

Alrex; Lotemax; CEHOAC; Chloromethyl 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate; Loteprednol; 17-ethoxycarbonyloxy-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate, Chloromethyl; Chloromethyl 17 ethoxycarbonyloxy 11 hydroxy 3 oxoandrosta 1,4 diene 17 carboxylate; Etabonate, Loteprednol

Networked: 109 relevant articles (33 outcomes, 38 trials/studies)

Relationship Network

Drug Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Androstanes: 11
      - Androstenes: 5
        Androstadienes: 1
        Loteprednol Etabonate: 109

Experts

1.	Comstock, Timothy L: 7 articles (04/2017 - 01/2008)
2.	Fong, Raymond: 4 articles (01/2019 - 01/2012)
3.	Holland, Edward J: 4 articles (09/2014 - 09/2004)
4.	Vittitow, Jason L: 3 articles (08/2020 - 10/2018)
5.	Sheppard, John D: 3 articles (09/2014 - 02/2011)
6.	Siou-Mermet, Raphaele: 3 articles (02/2014 - 01/2012)
7.	Rajpal, Rajesh K: 3 articles (10/2013 - 06/2011)
8.	Erb, Tara: 3 articles (02/2013 - 01/2011)
9.	Barabino, Stefano: 2 articles (07/2022 - 01/2019)
10.	Mah, Francis S: 2 articles (12/2021 - 01/2007)

Related Diseases

1.	Inflammation (Inflammations) 10/01/2018 - "In this study, submicron loteprednol etabonate gel 0.38% appeared safe and effective in the treatment of postoperative inflammation and pain whether instilled 2 times or 3 times a day." 11/01/1998 - "Loteprednol Etabonate Post-operative Inflammation Study Group 1." 09/01/1998 - "The Loteprednol Etabonate Postoperative Inflammation Study Group 2." 11/01/1998 - "Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. " 10/01/1998 - "Loteprednol etabonate: clinical potential in the management of ocular inflammation."
2.	Cataract (Cataracts) 01/01/2019 - "Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies." 10/01/2013 - "Loteprednol etabonate ophthalmic gel 0.5% following cataract surgery: integrated analysis of two clinical studies." 11/01/2018 - "There may be an additional short-term benefit of loteprednol gel in protecting the ocular surface after cataract surgery." 02/01/2013 - "Patients with anterior chamber cell (ACC) grade 2 or higher after cataract surgery were randomized to loteprednol etabonate 0.5% gel or vehicle 4 times a day for 14 days. " 09/01/1998 - "This study aimed to compare the efficacy and safety of loteprednol etabonate (LE) 0.5% to placebo (vehicle) in controlling the anterior chamber cell and flare reaction in patients undergoing cataract surgery with intraocular lens (IOL) implantation. "
3.	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 06/01/1997 - "Loteprednol etabonate is generally effective in prophylaxis of seasonal allergic conjunctivitis and has an acceptable safety profile." 02/01/1999 - "A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis." 12/01/1998 - "Furthermore, based upon a dose-response study in this model, 0.2% loteprednol etabonate was selected for further evaluation in environmental seasonal allergic conjunctivitis studies." 10/01/1998 - "Furthermore, a single placebo-controlled trial has shown that loteprednol etabonate 0.5% has prophylactic efficacy in patients with a history of seasonal allergic conjunctivitis. " 08/01/1998 - "The objective of this study was to evaluate the effects of 0.2% loteprednol etabonate in reducing the signs and symptoms of seasonal allergic conjunctivitis. "
4.	Pain (Aches) 01/01/2021 - "Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery." 02/01/2013 - "Significant treatment differences for complete resolution of ACC and grade 0 pain favoring loteprednol etabonate were also found on day 15 and day 18. " 02/01/2013 - "On day 8, 30.5% of patients in the loteprednol etabonate group and 16.3% of patients in the vehicle group had complete resolution of ACC, whereas 72.9% and 41.9%, respectively, had grade 0 pain (both P<.001). " 04/01/2020 - "Thus, loteprednol etabonate gel 0.38% extends the treatment options available in resolving post-operative inflammation and pain in patients who have undergone ocular surgery." 04/01/2020 - "Complete resolution of pain was seen as early as post-operative day 3. Treatment-related ocular adverse events in the loteprednol etabonate gel 0.38% group occurred in < 1% of subjects and included one incidence each of photophobia, cystoid macular oedema, eyelid oedema and instillation site pain. "
5.	Dry Eye Syndromes (Dry Eye Syndrome) 07/01/2019 - "There was a significant difference in the symptoms and signs of dry eye in the group receiving combination of loteprednol 0.5% and Cs 0.05% as compared to the group receiving Cs alone evident by greater reduction in OSDI score, corneal staining, and improvement in TBUT and Schirmer's test values over a follow-up of 6 months. " 02/01/2012 - "[Study on the treatment of dry eye with Loteprednol Etabonate]." 07/01/2022 - "To evaluate the effect of tapered doses of loteprednol-etabonate in dry eye disease patients. " 02/01/2022 - "Loteprednol etabonate: a formulation for short-term use in inflammatory flares in dry eye disease." 01/01/2021 - "Loteprednol 0.25% (Eysuvis) for dry eye disease."

Related Drugs and Biologics

1.	Suspensions
2.	Cyclosporine (Ciclosporin)
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Dexamethasone (Maxidex)
5.	Tobramycin (Nebcin)
6.	prednisolone acetate
7.	difluprednate
8.	Ophthalmic Solutions (Eye Drops)
9.	Steroids
10.	Flurbiprofen (Froben)

Related Therapies and Procedures

1.	Contact Lenses
2.	Intraocular Lenses (Intraocular Lens)
3.	Cataract Extraction
4.	Hematopoietic Stem Cell Transplantation
5.	Therapeutics